TLR7 and systemic lupus erythematosus: Using TLR antagonists or anti-TLR monoclonal antibodies to selectively prevent extracellular or endosomal TLR ligation has become an attractive treatment strategy for SLE, including TLR7 blockers (IRS661, DS-7011a), TLR7/8/9 antagonists (chloroquine), TLR7/8 blockers (Afimetoran, Enpatoran, E6742) and TLR2/4 inhibitors (vitamin D3) (98, 99).